3 active not recruiting, 2 completed, 2 recruiting, 1 terminated. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Active not recruiting 3, Completed 2, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Clear Cell Renal Cell Carcinoma: new trials by email Literature Review of Clear Cell Renal Cell Carcinoma trials Research Report on Clear Cell Renal Cell Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC piflufolastat F 18 - Clear Cell Renal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Lantheus Medical Imaging | 2025-11-01 | 2025-12-10 | |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer Pembrolizumab, Tivozanib, Biospecimen Collection - Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC) | Phase 3 | Recruiting | Alliance for Clinical Trials in Oncology | 1040 | 2025-03-14 | 2026-09-02 |
| 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study 89Zr-TLX250 PET/CT - Clear Cell Renal Cell Carcinoma | Phase 3 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 82 | 2024-11-06 | 2024-12-27 |
| A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread Nivolumab and rHuPH20, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 3 | Active not recruiting | Bristol-Myers Squibb | 681 | 2021-05-21 | 2026-09-22 |
| 89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study 89Zr-girentuximab - Clear Cell Renal Cell Carcinoma | Phase 3 | Completed | Telix Pharmaceuticals (Innovations) Pty Limited | 300 | 2019-08-15 | 2024-05-17 |
| Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study Biospecimen Collection, Bone Scan, Cabozantinib - Clear Cell Renal Cell Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 1175 | 2019-06-07 | 2026-10-26 |
| Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Computed Tomography, Magnetic Resonance Imaging, Pazopanib Hydrochloride - Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v7 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 129 | 2012-08-08 | 2026-10-26 |
| Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Bevacizumab, Everolimus, Laboratory Biomarker Analysis - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 3 | Terminated | National Cancer Institute (NCI) | 77 | 2010-09-15 | 2019-03-06 |
| Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Laboratory Biomarker Analysis, Placebo, Quality-of-Life Assessment - Clear Cell Renal Cell Carcinoma, Stage I Renal Cell Cancer AJCC v6 and v7 | Phase 3 | Completed | National Cancer Institute (NCI) | 1943 | 2006-04-24 | 2026-06-23 |
Carcinoma, Renal Cell (9) · Kidney Neoplasms (1) · Lymphatic Metastasis (1)
Adenocarcinoma (9) · Carcinoma (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Kidney Diseases (9) · Male Urogenital Diseases (9) · Neoplasms (9) · Neoplasms by Histologic Type (9) · Neoplasms by Site (9) · Neoplasms, Glandular and Epithelial (9) · Urogenital Diseases (9) · Urogenital Neoplasms (9) · Urologic Diseases (9) · Urologic Neoplasms (9) · Kidney Neoplasms (8)
Magnetic Resonance Spectroscopy (2) · Nivolumab (2) · 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid (1) · Bevacizumab (1) · Biopsy (1) · CTLA-4 Antigen (1) · Disulfides (1) · Everolimus (1) · Immunoglobulin G (1) · Ipilimumab (1) · Sorafenib (1) · Specimen Handling (1) · Sunitinib (1) · cabozantinib (1) · pazopanib (1)
National Cancer Institute (NCI) (4) · Telix Pharmaceuticals (Innovations) Pty Limited (2) · Alliance for Clinical Trials in Oncology (1) · Bristol-Myers Squibb (1) · Lantheus Medical Imaging (1)
United States (8) · Canada (2) · France (2) · Puerto Rico (2) · Turkey (Türkiye) (2) · Argentina (1) · Australia (1) · Belgium (1) · Brazil (1) · Chile (1) · China (1) · Czechia (1) · Finland (1) · Ireland (1) · Italy (1)
Andrew Scott, MD (1) · Bulent Akdogan, MD (1) · Bulent Onal, MD (1) · Carlos Artigas Guix, MD (1) · David Chan (1) · Declan Murphy, MD (1) · Francoise Brodere, MD (1) · George Philips (1) · Howard Gurney, MD (1) · Jean-Christophe Bernhard, MD (1) · Karolien Goffin, MD (1) · Leonard J Appleman (1) · Linda Heijmen, MD (1) · Marcel Stokkel, MD (1)
PMID 26969090, PMID 28278333, PMID 28945839, PMID 31703971, PMID 34405965, PMID 34480522, PMID 35304832, PMID 35383907, PMID 37433436, PMID 38531002, PMID 39270701, PMID 39288844, PMID 40408016
U10CA021115 (2), U10CA180820 (2), U10CA180821 (2), U10CA031946 (1), U10CA180830 (1), U24CA196172 (1)